A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants

NCT07254728 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus Infections

Interventions

BIOLOGICAL: VXA-G1.1-NN
BIOLOGICAL: VXA-G2.4-NS
BIOLOGICAL: Placebo Tablets

Sponsor

Vaxart